PE20181159A1 - Proteinas de fusion para tratar trastornos metabolicos - Google Patents
Proteinas de fusion para tratar trastornos metabolicosInfo
- Publication number
- PE20181159A1 PE20181159A1 PE2018001106A PE2018001106A PE20181159A1 PE 20181159 A1 PE20181159 A1 PE 20181159A1 PE 2018001106 A PE2018001106 A PE 2018001106A PE 2018001106 A PE2018001106 A PE 2018001106A PE 20181159 A1 PE20181159 A1 PE 20181159A1
- Authority
- PE
- Peru
- Prior art keywords
- fusion proteins
- metabolic disorders
- treat metabolic
- fgf21
- treat
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title abstract 2
- 108020001507 fusion proteins Proteins 0.000 title abstract 2
- 208000030159 metabolic disease Diseases 0.000 title abstract 2
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 abstract 3
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
La invencion se refiere a la identificacion de proteinas de fusion que comprenden variantes polipeptidicas y proteicas del factor de crecimiento de fibroblastos 21 (FGF21) que tienen propiedades farmaceuticas mejoradas. Tambien se describen metodos para el tratamiento de trastornos asociados con el FGF21, incluyendo trastornos metabolicos
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161539280P | 2011-09-26 | 2011-09-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20181159A1 true PE20181159A1 (es) | 2018-07-19 |
Family
ID=46970456
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2018001106A PE20181159A1 (es) | 2011-09-26 | 2012-09-26 | Proteinas de fusion para tratar trastornos metabolicos |
PE2014000418A PE20141551A1 (es) | 2011-09-26 | 2012-09-26 | Proteinas de fusion para tratar trastornos metabolicos |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2014000418A PE20141551A1 (es) | 2011-09-26 | 2012-09-26 | Proteinas de fusion para tratar trastornos metabolicos |
Country Status (41)
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008012525A1 (en) | 2006-07-25 | 2008-01-31 | Lipoxen Technologies Limited | Derivatisation of granulocyte colony-stimulating factor |
DK2068909T3 (da) | 2007-03-30 | 2012-08-06 | Ambrx Inc | Modificerede FGF-21-polypeptider og anvendelse heraf |
WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
DK3590949T3 (da) | 2010-10-01 | 2022-07-11 | Modernatx Inc | Ribonukleinsyrer indeholdende n1-methyl-pseudouracil og anvendelse heraf |
US8710200B2 (en) | 2011-03-31 | 2014-04-29 | Moderna Therapeutics, Inc. | Engineered nucleic acids encoding a modified erythropoietin and their expression |
MY163674A (en) | 2011-07-01 | 2017-10-13 | Ngm Biopharmaceuticals Inc | Compositions, uses and method for treatment of metabolic disorders and diseases |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US9458214B2 (en) | 2011-09-26 | 2016-10-04 | Novartis Ag | Dual function fibroblast growth factor 21 proteins |
US9006400B2 (en) * | 2011-09-26 | 2015-04-14 | Novartis Ag | Fibroblast growth factor-21-Fc fusion proteins |
RU2648950C2 (ru) | 2011-10-03 | 2018-04-02 | Модерна Терапьютикс, Инк. | Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение |
US20130156849A1 (en) | 2011-12-16 | 2013-06-20 | modeRNA Therapeutics | Modified nucleoside, nucleotide, and nucleic acid compositions |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
WO2013151667A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
RS63237B1 (sr) | 2012-11-26 | 2022-06-30 | Modernatx Inc | Terminalno modifikovana rnk |
EP3798228A1 (en) | 2012-11-28 | 2021-03-31 | NGM Biopharmaceuticals, Inc. | Compositions and methods for treatment of metabolic disorders and diseases |
US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
NZ630469A (en) | 2012-12-27 | 2017-02-24 | Ngm Biopharmaceuticals Inc | Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모더나 세라퓨틱스, 인코포레이티드 | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 |
WO2015057908A1 (en) | 2013-10-18 | 2015-04-23 | Novartis Ag | Methods of treating diabetes and related disorders |
US10369199B2 (en) | 2013-10-28 | 2019-08-06 | Ngm Biopharmaceuticals, Inc. | Methods of using variants of FGF19 polypeptides for the treatment of cancer |
PT3097122T (pt) | 2014-01-24 | 2020-07-21 | Ngm Biopharmaceuticals Inc | Anticorpos de ligação de domínio 2 de beta klotho e métodos de utilização dos mesmos |
EP3125921B1 (en) * | 2014-03-11 | 2020-07-08 | Novartis AG | Fgf21 variants for use in treating hiv-haart induced partial lipodystrophy |
WO2015183890A2 (en) | 2014-05-28 | 2015-12-03 | Ngm Biopharmaceuticals, Inc. | Methods and compositions for the treatment of metabolic disorders and diseases |
AU2015277438B2 (en) | 2014-06-16 | 2020-02-27 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
RU2729161C2 (ru) * | 2014-10-23 | 2020-08-04 | ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. | Фармацевтические композиции, содержащие варианты пептидов, и способы их применения |
US9434778B2 (en) | 2014-10-24 | 2016-09-06 | Bristol-Myers Squibb Company | Modified FGF-21 polypeptides comprising an internal deletion and uses thereof |
US10434144B2 (en) | 2014-11-07 | 2019-10-08 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
KR20160088656A (ko) | 2015-01-16 | 2016-07-26 | 주식회사유한양행 | 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물 |
US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
JP6940479B2 (ja) | 2015-08-03 | 2021-09-29 | ノバルティス アーゲー | Fgf21関連障害を処置する方法 |
AU2016353988B2 (en) | 2015-11-09 | 2019-09-26 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders |
TW201731867A (zh) | 2015-12-02 | 2017-09-16 | 賽諾菲公司 | Fgf21變異體 |
MX2018014256A (es) * | 2016-05-20 | 2019-08-16 | Harvard College | Metodos de terapia genica para enfermedades y condiciones relacionadas con la edad. |
WO2017205517A1 (en) * | 2016-05-25 | 2017-11-30 | Board Of Regents, The University Of Texas System | Methods and compositions for the treatment of secretory disorders |
EP3502143A4 (en) | 2016-08-19 | 2020-07-15 | Ampsource Biopharma Shanghai Inc. | BINDING PEPTIDE FOR THE CONSTRUCTION OF A FUSION PROTEIN |
CN107759694B (zh) * | 2016-08-19 | 2023-01-13 | 安源医药科技(上海)有限公司 | 双特异性抗体及其制备方法与用途 |
CN106279437B (zh) | 2016-08-19 | 2017-10-31 | 安源医药科技(上海)有限公司 | 高糖基化人凝血因子viii融合蛋白及其制备方法与用途 |
US11370841B2 (en) | 2016-08-26 | 2022-06-28 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
KR102657457B1 (ko) | 2016-12-22 | 2024-04-12 | 사노피 | 최적화된 활성 비율을 갖는 fgf21 화합물/glp-1r 작용제 조합물 |
EP3596130A4 (en) * | 2017-03-14 | 2020-12-30 | Sunshine Lake Pharma Co., Ltd. | DOUBLE TARGET FUSION PROTEINS WITH FC PORTION OF AN IMMUNE LOBULIN |
CN107050429B (zh) * | 2017-04-01 | 2020-12-15 | 杭州生物医药创新研究中心 | 人成纤维生长因子21在制备用于治疗脑卒中药物中的应用 |
CA3062473A1 (en) * | 2017-05-05 | 2018-11-08 | Trefoil Therapeutics, Inc. | Recombinant modified fibroblast growth factors and therapeutic uses thereof |
CN115109166A (zh) * | 2017-11-24 | 2022-09-27 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的多结构域活性蛋白 |
CN111518770B (zh) | 2017-12-19 | 2023-01-06 | 北京吉源生物科技有限公司 | 一种表达glp1和fgf21的干细胞及其用途 |
IL307483A (en) * | 2017-12-22 | 2023-12-01 | Novartis Ag | Methods for treating metabolic disorders with FGF21 variants |
AU2019218147B2 (en) | 2018-02-08 | 2023-06-08 | Sunshine Lake Pharma Co., Ltd. | FGF21 variant, fusion protein and application thereof |
SG11202013240RA (en) | 2018-07-03 | 2021-01-28 | Bristol Myers Squibb Co | Fgf21 formulations |
CN111195234B (zh) * | 2018-11-16 | 2022-08-26 | 鲁南制药集团股份有限公司 | 一种重组FGF21-Fc融合蛋白冻干粉制剂 |
EP3736574A1 (en) * | 2019-05-07 | 2020-11-11 | Atlas Antibodies AB | A formulation comprising an isotope labeled fusion polypeptide |
CN114853908B (zh) | 2019-05-16 | 2024-06-07 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的融合蛋白 |
CN112386575B (zh) * | 2019-08-19 | 2023-03-21 | 鲁南制药集团股份有限公司 | 一种代谢调节融合蛋白的冻干制剂 |
US11058725B2 (en) | 2019-09-10 | 2021-07-13 | Obsidian Therapeutics, Inc. | CA2 compositions and methods for tunable regulation |
CA3164941A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Combination treatment of liver diseases using integrin inhibitors |
JP6924291B2 (ja) | 2020-01-21 | 2021-08-25 | シャープ株式会社 | 端末装置、方法、および、集積回路 |
US11981718B2 (en) | 2020-05-27 | 2024-05-14 | Ampsource Biopharma Shanghai Inc. | Dual-function protein for lipid and blood glucose regulation |
WO2022101853A1 (en) | 2020-11-16 | 2022-05-19 | Novartis Ag | Method of determining liver fibrosis |
CN113265007B (zh) * | 2021-06-10 | 2022-02-15 | 江南大学 | 一种治疗代谢疾病的融合蛋白及其制备方法和应用 |
CN115286705B (zh) * | 2021-12-30 | 2024-05-10 | 长江大学 | 一种黄鳝成纤维细胞因子21重组蛋白及其制备方法和应用 |
WO2023245543A1 (en) * | 2022-06-23 | 2023-12-28 | Ampsource Biopharma Shanghai Inc. | Uses of fgf21 fusion proteins |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
DE3474511D1 (en) | 1983-11-01 | 1988-11-17 | Terumo Corp | Pharmaceutical composition containing urokinase |
EP0315456B1 (en) | 1987-11-05 | 1994-06-01 | Hybritech Incorporated | Polysaccharide-modified immunoglobulins having reduced immunogenic potential or improved pharmacokinetics |
US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
US5470582A (en) | 1992-02-07 | 1995-11-28 | Syntex (U.S.A.) Inc. | Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles |
US5234784A (en) | 1992-04-01 | 1993-08-10 | Eastman Kodak Company | Method of making a projection viewable transparency comprising an electrostatographic toner image |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
AU728657B2 (en) | 1996-03-18 | 2001-01-18 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
US7459540B1 (en) | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
US6716626B1 (en) | 1999-11-18 | 2004-04-06 | Chiron Corporation | Human FGF-21 nucleic acids |
AU1922101A (en) | 1999-11-18 | 2001-05-30 | Chiron Corporation | Human fgf-21 gene and gene expression products |
EP2295078A3 (en) | 1999-12-23 | 2011-03-23 | ZymoGenetics, L.L.C. | Method for treating inflammation |
WO2003011213A2 (en) | 2001-07-30 | 2003-02-13 | Eli Lilly And Company | Method for treating diabetes and obesity |
EP1673395A1 (en) | 2003-10-15 | 2006-06-28 | PDL BioPharma, Inc. | Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig |
AU2004303783A1 (en) * | 2003-12-10 | 2005-07-07 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
PL1751184T3 (pl) * | 2004-05-13 | 2010-02-26 | Lilly Co Eli | Białka fuzyjne FGF-21 |
CA2575753A1 (en) * | 2004-09-02 | 2006-03-16 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
US20080261875A1 (en) | 2005-01-21 | 2008-10-23 | Eli Lilly And Company | Method For Treating Cardiovascular Disease |
JOP20190083A1 (ar) * | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
ES2477543T3 (es) | 2008-10-24 | 2014-07-17 | Irm Llc | Pirrolina-carboxi-lisina generada biosintéticamente y modificaciones de proteínas específicas de sitio mediante derivatización química de restos de pirrolina-carboxi-lisina y pirrolisina |
WO2010129600A2 (en) | 2009-05-05 | 2010-11-11 | Amgen Inc. | Fgf21 mutants and uses thereof |
SG10201402038WA (en) * | 2009-05-05 | 2014-07-30 | Amgen Inc | FGF21 Mutants And Uses Thereof |
WO2010148142A1 (en) * | 2009-06-17 | 2010-12-23 | Amgen Inc. | Chimeric fgf19 polypeptides and uses thereof |
BR112012017164A2 (pt) | 2009-12-22 | 2019-09-24 | Novartis Ag | proteína de fusão de região constante de anticorpo-cd47 tetravalente |
DE102010038140B4 (de) * | 2010-10-13 | 2020-06-18 | Hettich-Heinze Gmbh & Co. Kg | Beschlag für eine Schiebetür |
US9023791B2 (en) | 2010-11-19 | 2015-05-05 | Novartis Ag | Fibroblast growth factor 21 mutations |
US9006400B2 (en) * | 2011-09-26 | 2015-04-14 | Novartis Ag | Fibroblast growth factor-21-Fc fusion proteins |
US9458214B2 (en) | 2011-09-26 | 2016-10-04 | Novartis Ag | Dual function fibroblast growth factor 21 proteins |
EP3125921B1 (en) | 2014-03-11 | 2020-07-08 | Novartis AG | Fgf21 variants for use in treating hiv-haart induced partial lipodystrophy |
-
2012
- 2012-09-25 US US13/626,194 patent/US9006400B2/en active Active
- 2012-09-25 JO JOP/2012/0279A patent/JO3476B1/ar active
- 2012-09-25 TW TW101135183A patent/TWI593708B/zh active
- 2012-09-25 UY UY34346A patent/UY34346A/es active IP Right Grant
- 2012-09-26 AR ARP120103553 patent/AR088044A1/es active IP Right Grant
- 2012-09-26 UA UAA201402419A patent/UA113856C2/uk unknown
- 2012-09-26 RS RS20211120A patent/RS62341B1/sr unknown
- 2012-09-26 SG SG11201400538QA patent/SG11201400538QA/en unknown
- 2012-09-26 BR BR112014007069-5A patent/BR112014007069B1/pt active IP Right Grant
- 2012-09-26 EA EA201490695A patent/EA039633B1/ru unknown
- 2012-09-26 HU HUE17201957A patent/HUE055584T2/hu unknown
- 2012-09-26 DK DK12768999.0T patent/DK2760475T3/en active
- 2012-09-26 SI SI201231952T patent/SI3321276T1/sl unknown
- 2012-09-26 IN IN2043DEN2014 patent/IN2014DN02043A/en unknown
- 2012-09-26 PT PT17201957T patent/PT3321276T/pt unknown
- 2012-09-26 DK DK17201957.2T patent/DK3321276T3/da active
- 2012-09-26 SI SI201231391T patent/SI2760475T1/sl unknown
- 2012-09-26 HR HRP20211575TT patent/HRP20211575T1/hr unknown
- 2012-09-26 CU CUP2015000171A patent/CU24314B1/es unknown
- 2012-09-26 MX MX2014003677A patent/MX350273B/es active IP Right Grant
- 2012-09-26 AU AU2012316052A patent/AU2012316052A1/en not_active Abandoned
- 2012-09-26 CA CA2849464A patent/CA2849464C/en active Active
- 2012-09-26 EP EP12768999.0A patent/EP2760475B1/en active Active
- 2012-09-26 ES ES12768999.0T patent/ES2689762T3/es active Active
- 2012-09-26 HU HUE12768999A patent/HUE039857T2/hu unknown
- 2012-09-26 LT LTEP12768999.0T patent/LT2760475T/lt unknown
- 2012-09-26 CN CN201280057789.3A patent/CN103945871B/zh active Active
- 2012-09-26 PT PT12768999T patent/PT2760475T/pt unknown
- 2012-09-26 JP JP2014532117A patent/JP6186361B2/ja active Active
- 2012-09-26 EP EP17201957.2A patent/EP3321276B1/en active Active
- 2012-09-26 PE PE2018001106A patent/PE20181159A1/es unknown
- 2012-09-26 RS RS20181146A patent/RS57868B1/sr unknown
- 2012-09-26 ES ES17201957T patent/ES2895080T3/es active Active
- 2012-09-26 AP AP2014007543A patent/AP2014007543A0/xx unknown
- 2012-09-26 CN CN201710255835.5A patent/CN107266579B/zh active Active
- 2012-09-26 KR KR1020147010946A patent/KR102085605B1/ko active IP Right Grant
- 2012-09-26 PL PL17201957T patent/PL3321276T3/pl unknown
- 2012-09-26 SG SG10201602339XA patent/SG10201602339XA/en unknown
- 2012-09-26 MY MYPI2014700650A patent/MY166059A/en unknown
- 2012-09-26 PL PL12768999T patent/PL2760475T3/pl unknown
- 2012-09-26 LT LTEP17201957.2T patent/LT3321276T/lt unknown
- 2012-09-26 PE PE2014000418A patent/PE20141551A1/es active IP Right Grant
- 2012-09-26 WO PCT/US2012/057384 patent/WO2013049247A1/en active Application Filing
-
2014
- 2014-03-07 ZA ZA2014/01700A patent/ZA201401700B/en unknown
- 2014-03-12 TN TNP2014000109A patent/TN2014000109A1/en unknown
- 2014-03-13 MA MA36824A patent/MA35437B1/fr unknown
- 2014-03-13 IL IL231533A patent/IL231533B/en active IP Right Grant
- 2014-03-25 CL CL2014000736A patent/CL2014000736A1/es unknown
- 2014-03-26 CR CR20140140A patent/CR20140140A/es unknown
- 2014-03-26 CO CO14064516A patent/CO6920257A2/es unknown
- 2014-03-26 CU CUP2014000034A patent/CU24206B1/es active IP Right Grant
- 2014-03-26 GT GT201400055A patent/GT201400055A/es unknown
- 2014-09-30 HK HK18110595.8A patent/HK1251238A1/zh unknown
-
2015
- 2015-02-24 US US14/630,206 patent/US9266935B2/en active Active
-
2016
- 2016-01-04 US US14/987,338 patent/US10076554B2/en active Active
- 2016-09-02 CL CL2016002215A patent/CL2016002215A1/es unknown
-
2017
- 2017-07-28 JP JP2017146984A patent/JP6567613B2/ja active Active
-
2018
- 2018-08-30 US US16/117,960 patent/US11129874B2/en active Active
- 2018-09-28 HR HRP20181558TT patent/HRP20181558T1/hr unknown
- 2018-10-03 CY CY181101017T patent/CY1120928T1/el unknown
-
2019
- 2019-07-31 JP JP2019141242A patent/JP2020007314A/ja not_active Withdrawn
-
2021
- 2021-03-08 UY UY0001039119A patent/UY39119A/es not_active Application Discontinuation
- 2021-08-24 US US17/410,307 patent/US11944664B2/en active Active
- 2021-10-06 CY CY20211100868T patent/CY1124697T1/el unknown
- 2021-10-25 AR ARP210102949A patent/AR123908A2/es unknown
-
2022
- 2022-01-11 JP JP2022002030A patent/JP7339372B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY39119A (es) | Proteínas de fusión para tratar trastornos metabólicos | |
CR20130234A (es) | Métodos de tratamiento de trastornos asociados con el fgf21 | |
CY1124309T1 (el) | Τροποποιημενα πολυπεπτιδια fgf-21 και χρησεις εξ αυτων | |
EA201490697A1 (ru) | Белки с двойной функцией для лечения метаболических расстройств | |
CL2018001897A1 (es) | Composiciones para modular la expresión de sod-1 (divisional solicitud 201602509) | |
CO7151525A2 (es) | Proteínas del factor 21 de crecimiento del fibroblasto | |
CR20150149A (es) | Proteínas de fusión para el tratamiento de un síndrome metabólico | |
EA201491856A1 (ru) | Терапевтическое применение белков фактора роста фибробластов 21 | |
MD20150109A2 (ro) | Construcţii proteice mitocondriale şi utilizările acestora | |
BR112017011226A2 (pt) | peptídeo, composição farmacêutica, processo para fabricação da composição farmacêutica | |
TN2013000211A1 (en) | Methods of treating fgf 21- associated disorders |